◎ Sugi Atlas

Atlas / Disease / Adenosquamous lung carcinoma

Adenosquamous lung carcinoma

disease
On this page

Also known as adenosquamous cell lung carcinomaadenosquamous lung cancerlung adenosquamous carcinoma

Summary

Adenosquamous lung carcinoma (MONDO:0004973) is a cancer with 2 cohort genes (2 CIViC-evidence somatic drivers) and 6 clinical trials. Molecularly, FGFR1 Amplification confers sensitivity to Pazopanib in Adenosquamous Lung Carcinoma (CIViC Level C). Top therapeutic interventions include erlotinib, ipilimumab, and pegfilgrastim.

At a glance

  • Classification: Cancer
  • Cohort genes: 2
  • Clinical trials: 6
  • Precision-medicine evidence (CIViC): 1 subtype–drug association

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameadenosquamous lung carcinoma
Mondo IDMONDO:0004973
EFOEFO:0000233
DOIDDOID:4829
NCITC9133
SNOMED CT707405009
UMLSC0279557
MedGen79006
Anatomy (UBERON)UBERON:0002048
Is cancer (heuristic)yes

Also known as: adenosquamous cell lung carcinoma · adenosquamous lung cancer · adenosquamous lung carcinoma · lung adenosquamous carcinoma

Data availability: 25 cell lines.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › squamous cell neoplasm › squamous cell carcinoma › adenosquamous carcinoma › adenosquamous lung carcinoma

Related subtypes (14): adenosquamous breast carcinoma, esophageal adenosquamous carcinoma, thymic adenosquamous carcinoma, Bartholin gland adenosquamous carcinoma, endometrial adenosquamous carcinoma, adenosquamous prostate carcinoma, pancreatic adenosquamous carcinoma, gastric adenosquamous carcinoma, cervical adenosquamous carcinoma, colorectal adenosquamous carcinoma, gallbladder adenosquamous carcinoma, salivary gland adenosquamous carcinoma, liver adenosquamous carcinoma, skin adenosquamous carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 17 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

GeneintOGen roleCancer typesCIViC
SLTMActCCRCC,LGGNOS,LUAD,NSCLC,OS,PRCC,RCCCIViC #52
FGFR1ActBLCA,GBM,OVT,PANCREAS,PAST,PGNG,WDTCCIViC #1885

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
FGFR1Orphanet:168953Myeloid/lymphoid neoplasm associated with FGFR1 rearrangement
FGFR1Orphanet:2117Hartsfield syndrome
FGFR1Orphanet:220386Semilobar holoprosencephaly
FGFR1Orphanet:2396Encephalocraniocutaneous lipomatosis
FGFR1Orphanet:251576Gliosarcoma
FGFR1Orphanet:251579Giant cell glioblastoma
FGFR1Orphanet:251615Pilomyxoid astrocytoma
FGFR1Orphanet:2645Osteoglosphonic dysplasia
FGFR1Orphanet:280200Microform holoprosencephaly
FGFR1Orphanet:314950Primary hypereosinophilic syndrome
FGFR1Orphanet:3157Septo-optic dysplasia spectrum
FGFR1Orphanet:3366Non-syndromic metopic craniosynostosis
FGFR1Orphanet:432Normosmic congenital hypogonadotropic hypogonadism
FGFR1Orphanet:478Kallmann syndrome
FGFR1Orphanet:93258Pfeiffer syndrome type 1
FGFR1Orphanet:93924Lobar holoprosencephaly
FGFR1Orphanet:99798Oligodontia

Cohort genes → proteins

2 cohort genes, 2 distinct canonical proteins.

Evidence partition

SubsetGenes
civic_only2

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
SLTMHGNC:20709ENSG00000137776Q9NWH9SAFB-like transcription modulatorcivic_evidence
FGFR1HGNC:3688ENSG00000077782P11362Fibroblast growth factor receptor 1civic_evidence

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
SLTMSAFB-like transcription modulatorWhen overexpressed, acts as a general inhibitor of transcription that eventually leads to apoptosis.
FGFR1Fibroblast growth factor receptor 1Tyrosine-protein kinase that acts as a cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of embryonic development, cell proliferation, differentiation and migration.

Protein-family classification

Druggable: 1 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.5

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Kinase113.9×0.142
Other/Unknown10.9×0.805

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
SLTMOther/UnknownnoRRM_dom, SAP_dom, Nucleotide-bd_a/b_plait_sf
FGFR1Kinaseyes2.7.10.1Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom, Ig_sub2

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)2
unknown0

Top tissues across cohort

TissueCohort genes
calcaneal tendon2
sural nerve1
tibia1
buccal mucosa cell1
stromal cell of endometrium1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
SLTM291ubiquitousmarkercalcaneal tendon, sural nerve, tibia
FGFR1292ubiquitousmarkerbuccal mucosa cell, stromal cell of endometrium, calcaneal tendon

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
FGFR15,693
SLTM2,598

Structural data

PDB: 1 · AlphaFold-only: 1 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
FGFR1P1136283

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
SLTMQ9NWH952.38

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 22. Enrichment computed across 2 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Signaling by FGFR1 amplification mutants15710.0×0.003FGFR1
FGFR1c and Klotho ligand binding and activation12855.0×0.003FGFR1
Signaling by plasma membrane FGFR1 fusions12855.0×0.003FGFR1
Epithelial-Mesenchymal Transition (EMT) during gastrulation11427.5×0.003FGFR1
FGFR1b ligand binding and activation11268.9×0.003FGFR1
Signaling by activated point mutants of FGFR11951.7×0.004FGFR1
FGFR1c ligand binding and activation1761.3×0.004FGFR1
Phospholipase C-mediated cascade: FGFR11671.8×0.004FGFR1
Downstream signaling of activated FGFR11543.8×0.004FGFR1
Signal transduction by L11519.1×0.004FGFR1
PI-3K cascade:FGFR11519.1×0.004FGFR1
SHC-mediated cascade:FGFR11496.5×0.004FGFR1
FRS-mediated FGFR1 signaling1456.8×0.004FGFR1
Formation of paraxial mesoderm1407.9×0.004FGFR1
Negative regulation of FGFR1 signaling1368.4×0.004FGFR1
Signaling by FGFR1 in disease1292.8×0.004FGFR1
PI3K Cascade1271.9×0.004FGFR1
NCAM signaling for neurite out-growth1271.9×0.004FGFR1
Constitutive Signaling by Aberrant PI3K in Cancer1126.9×0.009FGFR1
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling196.8×0.011FGFR1
PIP3 activates AKT signaling166.8×0.016FGFR1
RAF/MAP kinase cascade161.1×0.016FGFR1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
vitamin D3 metabolic process14213.0×0.004FGFR1
positive regulation of mitotic cell cycle DNA replication14213.0×0.004FGFR1
positive regulation of parathyroid hormone secretion14213.0×0.004FGFR1
regulation of extrinsic apoptotic signaling pathway in absence of ligand14213.0×0.004FGFR1
regulation of phosphate transport12808.7×0.004FGFR1
fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development12808.7×0.004FGFR1
regulation of lateral mesodermal cell fate specification12808.7×0.004FGFR1
ventricular zone neuroblast division12106.5×0.004FGFR1
negative regulation of fibroblast growth factor production12106.5×0.004FGFR1
positive regulation of phospholipase activity11685.2×0.004FGFR1
regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling11685.2×0.004FGFR1
diphosphate metabolic process11685.2×0.004FGFR1
chordate embryonic development11404.3×0.004FGFR1
positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway11404.3×0.004FGFR1
cementum mineralization11203.7×0.004FGFR1
auditory receptor cell development1936.2×0.004FGFR1
paraxial mesoderm development1842.6×0.004FGFR1
lung-associated mesenchyme development1842.6×0.004FGFR1
response to sodium phosphate1842.6×0.004FGFR1
outer ear morphogenesis1766.0×0.005FGFR1
branching involved in salivary gland morphogenesis1702.2×0.005FGFR1
organ induction1601.9×0.005FGFR1
mesenchymal cell proliferation1561.7×0.005FGFR1
positive regulation of endothelial cell chemotaxis1495.6×0.006FGFR1
cell projection assembly1468.1×0.006FGFR1
regulation of mRNA processing1443.5×0.006SLTM
regulation of postsynaptic density assembly1443.5×0.006FGFR1
positive regulation of vascular endothelial cell proliferation1421.3×0.006FGFR1
middle ear morphogenesis1351.1×0.007FGFR1
phosphatidylinositol-mediated signaling1351.1×0.007FGFR1

Therapeutics

Drug target analysis

Approved (phase 4): 2 · Phase ≥3: 2 · Phased (≥1): 2 · Undrugged: 0

Druggability breadth: 2 of 2 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

SymbolExample approved molecule
SLTMCABOZANTINIB
FGFR1PONATINIB

Top cohort targets by molecule count

SymbolMoleculesMax phase
FGFR1934
SLTM14

Drugs targeting cohort genes (top 30)

MoleculeMax phaseTargets in cohort
CABOZANTINIB4FGFR1, SLTM
PONATINIB4FGFR1
PEMIGATINIB4FGFR1
NINTEDANIB4FGFR1
FEDRATINIB4FGFR1
TIVOZANIB4FGFR1
LENVATINIB4FGFR1
AXITINIB4FGFR1
SORAFENIB4FGFR1
NICLOSAMIDE4FGFR1
INFIGRATINIB PHOSPHATE4FGFR1
INFIGRATINIB4FGFR1
REGORAFENIB4FGFR1
ENTRECTINIB4FGFR1
CAPIVASERTIB4FGFR1
VANDETANIB4FGFR1
NINTEDANIB ESYLATE4FGFR1
BRIGATINIB4FGFR1
ERDAFITINIB4FGFR1
UPADACITINIB4FGFR1
FUTIBATINIB4FGFR1
PAZOPANIB4FGFR1
SUNITINIB4FGFR1
DASATINIB4FGFR1
MIDOSTAURIN4FGFR1
LINIFANIB3FGFR1
SEMAXANIB3FGFR1
OLVEREMBATINIB3FGFR1
BRIVANIB ALANINATE3FGFR1
ORANTINIB3FGFR1

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
FGFR11,465Binding:1428, Functional:24, ADMET:13
SLTM14Binding:14

Cohort enzymes (BRENDA EC)

SymbolEC numbersNames
FGFR12.7.10.1receptor protein-tyrosine kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

SymbolChEMBL assays
FGFR11,465

Pharmacogenomics

Cohort genes with a PharmGKB record: 2; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

30 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

CompoundMax phaseCohort target (bioactivity)
CABOZANTINIB4FGFR1, SLTM
PONATINIB4FGFR1
PEMIGATINIB4FGFR1
NINTEDANIB4FGFR1
FEDRATINIB4FGFR1
TIVOZANIB4FGFR1
LENVATINIB4FGFR1
AXITINIB4FGFR1
SORAFENIB4FGFR1
NICLOSAMIDE4FGFR1
INFIGRATINIB PHOSPHATE4FGFR1
INFIGRATINIB4FGFR1
REGORAFENIB4FGFR1
ENTRECTINIB4FGFR1
CAPIVASERTIB4FGFR1
VANDETANIB4FGFR1
NINTEDANIB ESYLATE4FGFR1
BRIGATINIB4FGFR1
ERDAFITINIB4FGFR1
UPADACITINIB4FGFR1
FUTIBATINIB4FGFR1
PAZOPANIB4FGFR1
SUNITINIB4FGFR1
DASATINIB4FGFR1
MIDOSTAURIN4FGFR1
LINIFANIB3FGFR1
SEMAXANIB3FGFR1
OLVEREMBATINIB3FGFR1
BRIVANIB ALANINATE3FGFR1
ORANTINIB3FGFR1

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)2SLTM, FGFR1
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 6.

Phase distribution (across all retrieved trials)

PhaseTrials
PHASE24
PHASE2/PHASE31
PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT04929041PHASE2/PHASE3SUSPENDEDTesting the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
NCT00334815PHASE2ACTIVE_NOT_RECRUITINGCombination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00126581PHASE2COMPLETEDErlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT01294306PHASE2COMPLETEDMK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy
NCT02186847PHASE2COMPLETEDChemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT06602661PHASE1NOT_YET_RECRUITINGReinforced and Non-Reinforced Staple Lines in Fissureless Lobectomy

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
ERLOTINIB43
IPILIMUMAB41
PEGFILGRASTIM41

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 1 predictive associations from 1 curated evidence items; also 1 prognostic.

Molecular subtypeTherapyEffectLevelCIViC
FGFR1 AmplificationPazopanibSensitivity/ResponseCIViC CEID7811

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 73

This page pulls from 73 datasets indexed by BioBTree:

alphafoldantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticscellosauruschembl_activitychembl_assaychembl_documentchembl_moleculechembl_targetciviccivic_evidenceclingen_dosageclinical_trialsclinvarctd_gene_interactiondepmapdiamond_similaritydoidefoensemblentrezesm2_similarityfantom5_genefantom5_promotergenccgenerifgogtopdbgtopdb_interactiongwasgwas_studyhgncintactinterprointogenmedgenmeshmimmondomondochildmondoparentncitorphanetpatentpatent_compoundpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assayreactomerefseqrhearnacentralsctidscxa_expressionscxa_gene_experimentsignorstring_interactiontranscriptuberonufeatureumlsuniprot